

腎臟新知 2019 - 與各科之連結

Update need to know about nephrology 2019

– Link with all doctors working in hospital

李柏蒼

高雄榮民總醫院 腎臟科

For the rapid scientific and technological advances in renal care, we will advance your knowledge for a comprehensive review of the latest development in nephrology. In this talk, two important issues will be addressed including the new therapy for autosomal dominant polycystic kidney disease (ADPKD), and anticoagulant-related nephropathy. In the past, the treatment of ADPKD has been limited to the management of its symptoms and complications. Recently, the Taiwan Bureau of NHI approved tolvaptan as the first drug treatment to slow kidney function decline in adults at risk of rapidly progressing ADPKD. I will provide practical guidance and discuss steps that require consideration before and after prescribing tolvaptan to patients with ADPKD to ensure that this treatment is implemented safely and effectively. Anticoagulant-related nephropathy (ARN) is a newly recognized form of AKI in which over anticoagulation causes profuse glomerular hemorrhage, which manifests on renal biopsy as numerous renal tubules filled with red cells and red cell casts. In this talk, I will provide recommendations regarding the diagnosis and management of ARN on the basis of the best information available.